keyword
MENU ▼
Read by QxMD icon Read
search

Chemotherapy inducing anemia

keyword
https://www.readbyqxmd.com/read/28167659/targeting-btk-with-ibrutinib-in-relapsed-refractory-marginal-zone-lymphoma
#1
Ariela Noy, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher R Flowers, Franck Morschhauser, Graham P Collins, Shuo Ma, Morton Coleman, Shachar Peles, Stephen Smith, Jacqueline C Barrientos, Alina Smith, Brian Munneke, Isaiah Dimery, Darrin M Beaupre, Robert Chen
Marginal zone lymphoma (MZL) is a heterogeneous B-cell malignancy for which no standard treatment exists. MZL is frequently linked to chronic infection, which may induce B-cell receptor (BCR) signaling resulting in aberrant B-cell survival and proliferation. We conducted a multicenter, open-label, phase 2 study to evaluate the efficacy and safety of ibrutinib in previously treated MZL. Patients with histologically-confirmed MZL of all subtypes who received ≥1 prior therapy with an anti-CD20 antibody-containing regimen were treated with ibrutinib 560 mg orally once daily until progression or unacceptable toxicity...
February 6, 2017: Blood
https://www.readbyqxmd.com/read/28078434/a-retrospective-open-label-uncontrolled-study-of-epoetin-zeta-on-the-treatment-of-chemotherapy-induced-anemia-in-solid-tumors
#2
Constantinos E Alifieris, Kyriakos Orfanakos, Aristina Papanota, George P Stathopoulos, Nikolaos Sitaras, Dimitrios T Trafalis
PURPOSE: This is a single-center uncontrolled retrospective study to evaluate the efficacy and safety of the biosimilar epoetin zeta after approval in chemotherapy-induced anemia (CIA). METHODS: Patients screened were >18 years old suffering from solid malignancies and CIA with Hg ≤10 or <11 g/dl if symptomatic anemia. Patients had measurable disease by TNM and Eastern Cooperative Oncology Group (ECOG). Patients were treated for at least 12 weeks and the primary endpoint was to determine the incidence of blood transfusions, and secondarily, the overall safety and efficacy defined as ≥1 g/dl rise in Hb concentration or ≥40,000 cells/μl rise in reticulocyte count...
January 11, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27956157/ibrutinib-for-patients-with-rituximab-refractory-waldenstr%C3%A3-m-s-macroglobulinaemia-innovate-an-open-label-substudy-of-an-international-multicentre-phase-3-trial
#3
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T Heffner, Chaim Shustik, Ramón García-Sanz, Robert F Cornell, Carlos Fernández de Larrea, Jorge J Castillo, Miquel Granell, Marie-Christine Kyrtsonis, Veronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh, Jianling Li, Thorsten Graef, Elizabeth Bilotti, Steven Treon, Christian Buske
BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease. METHODS: This multicentre, open-label substudy was done at 19 sites in seven countries in adults aged 18 years and older with confirmed Waldenström's macroglobulinaemia, refractory to rituximab and requiring treatment...
February 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27903235/erythropoietin-enhances-the-cytotoxic-effect-of-hydrogen-peroxide-on-colon-cancer-cells
#4
Tankiewicz-Kwedlo Anna, Hermanowicz Justyna Magdalena, Surażynski Arkadiusz, Kwedlo Wojciech, Rożkiewicz Dariusz, Pawlak Krystyna, Domaniewski Tomasz, Pawlak Dariusz
BACKGROUND: Cancer patients treated with alkylating agents and radiotherapy are exposed to high level of reactive oxygen species (ROS) in tissues. ROS can involve superoxide free radicals, peroxynitrite, singlet oxygen, nitric oxide and hydrogen peroxide. It is well documented that increased exposure to oxygen through a high metabolic rate could lead to a shortened life span. Ionizing radiation, use of drugs and the development of cancer can lead to cancer-induced anemia. Recombinant human erythropoietin (Epo) supplementation is one of the methods for treating anemia...
November 15, 2016: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/27882724/efficacy-and-safety-of-darbepoetin-alfa-initiated-at-hemoglobin-%C3%A2-10%C3%A2-g-dl-in-patients-with-stage-iv-cancer-and-chemotherapy-induced-anemia
#5
Ralph V Boccia, David H Henry, Laura Belton, Chet Bohac, Hassan H Ghazal
Data on efficacy and safety of darbepoetin alfa (DA) administered at hemoglobin (Hb) ≤10 g/dL are limited. In this analysis, we examined DA's efficacy and safety in patients with Stage IV cancers and chemotherapy-induced anemia (CIA) initiated on DA at Hb ≤10 g/dL. Data for patients with Stage IV cancers and CIA and who initiated DA at Hb ≤10 g/dL were extracted from three phase 3 trials identified in a central database of Amgen-sponsored DA studies in CIA. Efficacy outcomes were assessed by achievement of Hb increases of ≥1 g/dL and ≥2 g/dL and red blood cell (RBC) or whole blood transfusion requirements...
December 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27872759/impact-of-moderate-intensity-aerobic-exercise-on-chemotherapy-induced-anemia-in-elderly-women-with-breast-cancer-a-randomized-controlled-clinical-trial
#6
Heba M Mohamady, Hany F Elsisi, Yasser M Aneis
Exercises are often recommended for patients suffering from anemia to improve physical conditioning and hematologic parameters. Hence, the present study aimed to investigate the impact of moderate intensity aerobic exercise on chemotherapy-induced anemia. Thirty elderly women with breast cancer underwent chemotherapy and were randomly assigned into two equal groups; Group A received aerobic exercise for 25-40 min at 50-70% of the maximum heart rate, 3 times/week for 12 weeks in addition to usual daily living activities, medication and nutritional support...
January 2017: Journal of Advanced Research
https://www.readbyqxmd.com/read/27822071/biosimilar-epoetin-for-the-management-of-chemotherapy-induced-anemia-in-elderly-patients
#7
Jean-Emmanuel Kurtz, Pierre Soubeyran, Mauricette Michallet, Elisabeth Luporsi, Hélène Albrand
INTRODUCTION: Chemotherapy-induced anemia (CIA) is a frequent complication among cancer patients, with elderly patients more likely to suffer severe effects. Biosimilar erythropoiesis-stimulating agents lower costs of supportive cancer treatment, and thus are particularly relevant in the elderly cancer population, which is growing rapidly worldwide. The goal of this subanalysis was to compare the tolerability and effectiveness of an epoetin biosimilar for treating CIA in patients <70 years old vs patients ≥70 years old...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27773819/fancd2-protects-against-bone-marrow-injury-from-ferroptosis
#8
Xinxin Song, Yangchun Xie, Rui Kang, Wen Hou, Xiaofang Sun, Michael W Epperly, Joel S Greenberger, Daolin Tang
Bone marrow injury remains a serious concern in traditional cancer treatment. Ferroptosis is an iron- and oxidative-dependent form of regulated cell death that has become part of an emerging strategy for chemotherapy. However, the key regulator of ferroptosis in bone marrow injury remains unknown. Here, we show that Fanconi anemia complementation group D2 (FANCD2), a nuclear protein involved in DNA damage repair, protects against ferroptosis-mediated injury in bone marrow stromal cells (BMSCs). The classical ferroptosis inducer erastin remarkably increased the levels of monoubiquitinated FANCD2, which in turn limited DNA damage in BMSCs...
October 20, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27577729/induction-chemotherapy-followed-by-radiotherapy-versus-concurrent-chemoradiotherapy-in-elderly-patients-with-nasopharyngeal-carcinoma-finding-from-a-propensity-matched-analysis
#9
Qi Zeng, Jie Wang, Xing Lv, Jie Li, Li-Jie Yin, Yan-Qun Xiang, Xiang Guo
BACKGROUND: To date, no guideline is proposed for elderly nasopharyngeal carcinoma (NPC) due to lack of prospective clinical trials. The present study comparing the survivals and toxicities in elderly NPC patients received either induction chemotherapy followed by radiotherapy(IC + RT) or concurrent chemoradiotherapy (CCRT) was therefore undertaken to provide a more accurate basis for future clinical practice. METHODS: The eligible elderly NPC patients were retrospectively enrolled...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27494133/identification-of-cell-type-specific-differences-in-erythropoietin-receptor-signaling-in-primary-erythroid-and-lung-cancer-cells
#10
Ruth Merkle, Bernhard Steiert, Florian Salopiata, Sofia Depner, Andreas Raue, Nao Iwamoto, Max Schelker, Helge Hass, Marvin Wäsch, Martin E Böhm, Oliver Mücke, Daniel B Lipka, Christoph Plass, Wolf D Lehmann, Clemens Kreutz, Jens Timmer, Marcel Schilling, Ursula Klingmüller
Lung cancer, with its most prevalent form non-small-cell lung carcinoma (NSCLC), is one of the leading causes of cancer-related deaths worldwide, and is commonly treated with chemotherapeutic drugs such as cisplatin. Lung cancer patients frequently suffer from chemotherapy-induced anemia, which can be treated with erythropoietin (EPO). However, studies have indicated that EPO not only promotes erythropoiesis in hematopoietic cells, but may also enhance survival of NSCLC cells. Here, we verified that the NSCLC cell line H838 expresses functional erythropoietin receptors (EPOR) and that treatment with EPO reduces cisplatin-induced apoptosis...
August 2016: PLoS Computational Biology
https://www.readbyqxmd.com/read/27457977/chronic-preclinical-safety-evaluation-of-epo-018b-a-pegylated-peptidic-erythropoiesis-stimulating-agent-in-monkeys-and-rats
#11
Xue-Lian Gong, Xiao-Lei Gu, Yong-Chun Chen, Hai Zhu, Zhen-Na Xia, Jian-Zhong Li, Guo-Cai Lu
EPO-018B, a synthetic peptide-based erythropoiesis stimulating agent (ESA), is mainly designed for treatment of anemia caused by chronic renal failure and chemotherapy against cancer. It overcomes the deficiencies of currently approved ESA, including the frequent administration of temperature-sensitive recombinant protein and anti-EPO antibody-mediated pure red cell aplasia (PRCA). This study was designed to evaluate the potential chronic toxicity of EPO-018B. Subcutaneous administration doses were designed as 0, 0...
September 15, 2016: Toxicology and Applied Pharmacology
https://www.readbyqxmd.com/read/27387766/iron-supplementation-for-chemotherapy-induced-anemia-in-patients-receiving-erythropoiesis-stimulating-agents
#12
COMPARATIVE STUDY
Rahul Mhaskar, Benjamin Djulbegovic
Clinical Question: What are the benefits and harms of iron supplementation alone and as an adjunct to erythropoiesis-stimulating agents (ESAs) compared with ESA alone in the treatment of chemotherapy-induced anemia? Bottom Line: Addition of iron to ESAs improves hematopoietic response, reduces the need for red blood cell transfusions, increases hemoglobin levels, and seems to be well tolerated. The subgroup analyses suggest the superiority of parenteral iron over oral iron supplementation in the treatment of chemotherapy-induced anemia...
November 1, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27195162/a-case-of-hyperammonemia-associated-with-high-dihydropyrimidine-dehydrogenase-activity
#13
Keiki Nagaharu, Kenji Ikemura, Yoshiki Yamashita, Hiroyasu Oda, Mikiya Ishihara, Yumiko Sugawara, Satoshi Tamaru, Toshiro Mizuno, Naoyuki Katayama
Over the past decades, 5-Fluorouracil (5-FU) has been widely used to treat several types of carcinoma, including esophageal squamous cell carcinoma. In addition to its common side effects, including diarrhea, mucositis, neutropenia, and anemia, 5-FU treatment has also been reported to cause hyperammonemia. However, the exact mechanism responsible for 5-FU-induced hyperammonemia remains unknown. We encountered an esophageal carcinoma patient who developed hyperammonemia when receiving 5-FU-containing chemotherapy but did not exhibit any of the other common adverse effects of 5-FU treatment...
2016: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/27167627/the-effect-of-chemotherapy-induced-anemia-on-dose-reduction-and-dose-delay
#14
Leila Family, Lanfang Xu, Hairong Xu, Kimberly Cannavale, Olivia Sattayapiwat, John H Page, Chet Bohac, Chun Chao
PURPOSE: To evaluate moderate (grade 2, hemoglobin <10 g/dl) and severe (grade 3+, hemoglobin <8 g/dl) anemia as potential risk factors for DDR in the first line course of chemotherapy. While chemotherapy-induced neutropenia has been shown to be associated with dose delay/reduction (DDR) in several studies, the effect of anemia is less well studied. METHODS: We identified 3955 Kaiser Permanente patients diagnosed with incident non-Hodgkin's lymphoma (n = 574), breast (n = 2043), lung (n = 463), gastric (n = 113), ovarian (n = 204), or colorectal cancers (n = 558) between 2010 and 2012...
October 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/27102406/predictors-of-chemotherapy-induced-toxicity-and-treatment-outcomes-in-elderly-versus-younger-patients-with-metastatic-castration-resistant-prostate-cancer
#15
Per Kongsted, Inge Marie Svane, Henriette Lindberg, Lisa Sengeløv
BACKGROUND: In the present study, we examined possible predictors of chemotherapy-induced toxicity, treatment outcomes, and the consequences of dose reductions in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving standard docetaxel. PATIENTS AND METHODS: Medical records from 421 consecutive patients treated with first-line docetaxel (75 mg/m(2) every 3 weeks) and low-dose prednisolone from 2007 to 2013 at Herlev University Hospital were reviewed...
March 24, 2016: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/27076919/cataloging-antineoplastic-agents-according-to-their-effectiveness-against-platinum-resistant-and-platinum-sensitive-ovarian-carcinoma-cell-lines
#16
Kimiko Ishiguro, Yong-Lian Zhu, Z Ping Lin, Philip G Penketh, Krishnamurthy Shyam, Rui Zhu, Raymond P Baumann, Alan C Sartorelli, Thomas J Rutherford, Elena S Ratner
Although epithelial ovarian cancers (EOCs) are initially treated with platinum-based chemotherapy, EOCs vary in platinum responsiveness. Cataloging antineoplastic agents according to their effectiveness against platinum-resistant and platinum-sensitive EOC cell lines is valuable for development of therapeutic strategies to avoid platinum inefficacy and to exploit platinum sensitivity. TOV-21G devoid of FANCF expression, OV-90 and SKOV-3 were employed as examples of platinum-sensitive, platinum-intermediate and platinum-resistant cell lines, respectively...
2016: Journal of Translational Science
https://www.readbyqxmd.com/read/27073478/effects-of-decitabine-on-megakaryocyte-maturation-in-patients-with-myelodysplastic-syndromes
#17
Kai Ding, Rong Fu, Hui Liu, Deepak Anil Nachnani, Zong-Hong Shao
Thrombocytopenia is a common, often fatal complication experienced by patients with myelodysplastic syndromes (MDS). 5-aza-2'-deoxycytidine (decitabine) has been used to treat MDS patients with thrombocytopenia with a response rate of 45-50%. However, the mechanism of its effects on megakaryocytes remains unclear. In the present study, the effect of decitabine on megakaryocyte maturation was investigated. A total of 20 MDS patients diagnosed with thrombocytopenia were enrolled, including 16 refractory anemia with excess blasts (RAEB)-1 patients and 4 RAEB-2 patients], in addition to 20 leukemia patients that had achieved complete remission and 20 healthy donors...
April 2016: Oncology Letters
https://www.readbyqxmd.com/read/27064021/minimally-myelosuppressive-asparaginase-containing-induction-regimen-for-treatment-of-a-jehovah-s-witness-with-mutant-idh1-npm1-nras-acute-myeloid-leukemia
#18
Ashkan Emadi, Najeebah A Bade, Brandi Stevenson, Zeba Singh
Treatment of patients with acute myeloid leukemia (AML) who do not wish to accept blood product transfusion, including Jehovah's Witnesses, is extremely challenging. The use of conventional chemotherapy for induction of complete remission (CR) results in profound anemia and thrombocytopenia requiring frequent transfusions of blood products, without which such treatment will be life-threatening. Finding a well tolerable, minimally myelosuppressive induction regimen for such patients with AML is a clear example of area of unmet medical need...
March 10, 2016: Pharmaceuticals
https://www.readbyqxmd.com/read/27057370/paclitaxel-induced-mds-and-aml-a-case-report-and-literature-review
#19
Udit Bhaskar Bhatnagar, Daulath Singh, Alexy Glazyrin, Jill Moormeier
Therapy related acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) have been classically linked to alkylating agents and topoisomerase inhibitors. They constitute about 1% of all AMLs. There is less evidence on association of taxanes (paclitaxel and docetaxel) with these myeloid neoplasms. We present a case of paclitaxel therapy related acute myelogenous leukemia after treatment of endometrial cancer with a regimen containing paclitaxel and carboplatin. A 63-year-old female underwent surgery followed by a total of 6 cycles of chemotherapy with carboplatin and paclitaxel...
2016: Case Reports in Oncological Medicine
https://www.readbyqxmd.com/read/26993769/genetic-variants-of-gadd45a-gadd45b-and-mapk14-predict-platinum-based-chemotherapy-induced-toxicities-in-chinese-patients-with-non-small-cell-lung-cancer
#20
Ming Jia, Meiling Zhu, Mengyun Wang, Menghong Sun, Ji Qian, Fei Ding, Jianhua Chang, Qingyi Wei
The JNK and P38α pathways play a crucial role in tissue homeostasis, apoptosis and autophagy under genotoxic stresses, but it is unclear whether single nucleotide polymorphisms (SNPs) of genes in these pathways play a role in platinum-based chemotherapy-induced toxicities in patients with advanced non-small cell lung cancer (NSCLC). We genotyped 11 selected, independent, potentially functional SNPs of nine genes in the JNK and P38α pathways in 689 patients with advanced NSCLC treated with platinum-combination chemotherapy regimens...
May 3, 2016: Oncotarget
keyword
keyword
51678
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"